Charles Schwab Investment Management Inc Cerevel Therapeutics Holdings, Inc. Transaction History

Charles Schwab Investment Management Inc

$519 Billion
Q2 2024

A detailed history of Charles Schwab Investment Management Inc transactions in Cerevel Therapeutics Holdings, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 522,930 shares of CERE stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

522,930

Previous 665,831 21.46%

Holding current value

Previous $28.1 Million 24.03%

% of portfolio

0.0%

Previous 0.01%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$38.96 - $42.75 $5.57 Million - $6.11 Million	-142,901 Reduced 21.46%	522,930 $21.4 Million
Q1 2024 May 08, 2024	BUY	$40.88 - $43.27 $674,438 - $713,868	16,498 Added 2.54%	665,831 $28.1 Million
Q4 2023 Feb 06, 2024	BUY	$20.27 - $42.44 $2.68 Million - $5.61 Million	132,089 Added 25.54%	649,333 $27.5 Million
Q3 2023 Nov 08, 2023	BUY	$20.26 - $31.91 $309,187 - $486,978	15,261 Added 3.04%	517,244 $11.3 Million
Q2 2023 Aug 09, 2023	BUY	$23.9 - $35.38 $358,500 - $530,700	15,000 Added 3.08%	501,983 $16 Million
Q1 2023 May 11, 2023	BUY	$22.82 - $35.32 $37,401 - $57,889	1,639 Added 0.34%	486,983 $11.9 Million
Q4 2022 Feb 13, 2023	BUY	$25.35 - $31.96 $445,095 - $561,153	17,558 Added 3.75%	485,344 $15.3 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $1.84 Million - $2.99 Million	72,301 Added 18.28%	467,786 $13.2 Million
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $472,692 - $851,626	22,924 Added 6.15%	395,485 $10.5 Million
Q1 2022 May 13, 2022	BUY	$23.5 - $35.38 $221,863 - $334,022	9,441 Added 2.6%	372,561 $13 Million
Q4 2021 Feb 11, 2022	BUY	$29.21 - $44.64 $330,423 - $504,967	11,312 Added 3.22%	363,120 $11.8 Million
Q3 2021 Nov 16, 2021	BUY	$21.26 - $38.85 $2.13 Million - $3.9 Million	100,315 Added 39.89%	351,808 $10.4 Million
Q2 2021 Aug 16, 2021	BUY	$12.56 - $29.69 $1 Million - $2.37 Million	79,823 Added 46.5%	251,493 $6.44 Million
Q1 2021 May 17, 2021	BUY	$12.37 - $17.74 $61,355 - $87,990	4,960 Added 2.98%	171,670 $2.36 Million
Q4 2020 Feb 16, 2021	BUY	$9.82 - $18.27 $1.64 Million - $3.05 Million	166,710 New	166,710 $2.77 Million

Others Institutions Holding CERE

# of Institutions

269

Shares Held

155M

Call Options Held

2.19M

Put Options Held

3.92M

View Full List

About Cerevel Therapeutics Holdings, Inc.

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

More about CERE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Cerevel Therapeutics Holdings, Inc. Transaction History